<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02683291</url>
  </required_header>
  <id_info>
    <org_study_id>16966913.6.0000.5411</org_study_id>
    <nct_id>NCT02683291</nct_id>
  </id_info>
  <brief_title>Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients</brief_title>
  <official_title>Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Associação Médico Espírita de Botucatu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Associação Médico Espírita de Botucatu</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no consensus on the best immunosuppressive regimen in elderly people. The aim of
      this study will be to evaluate the efficacy of sirolimus associated with tacrolimus in
      elderly kidney transplant recipients. The investigators will conduct a single-center
      prospective randomized study comparing the combination of tacrolimus with sirolimus at
      reduced dose rate (tacrolimus + sirolimus group) against tacrolimus with mycophenolate
      (tacrolimus + mycophenolate group). The investigators will include all kidney transplant
      patients over 60 years of age. The investigators will evaluate estimated glomerular
      filtration rate and incidence of cytomegalovirus in 12 month follow-up.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study Design

      This will be a single-center, prospective, 12-month randomized controlled trial aiming to
      compare sirolimus associated with tacrolimus in elderly renal transplant patients as to
      safety and incidence of cytomegalovirus (CMV) infection.

      Treatments

      In the control group (Tacrolimus + Mycophenolate) the investigators will use tacrolimus
      (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8ng/ml at the third
      month and then 3-7ng/ml from the third month to the 12th month) and mycophenolate sodium 720
      mg twice daily. A dose reduction of mycophenolate sodium to 720 mg/day will be accepted due
      to possible side effects of the drug.

      In the treatment group (Tacrolimus + sirolimus) the investigators will use tacrolimus
      (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8 ng/ml at the
      third month and then 3-7 ng/ml from the third month to the 12th month) and sirolimus 2 mg/day
      (adjusted serum levels at 4-8 ng/ml throughout the study period).

      In all groups, patients will receive prednisone 30 mg/day (in the first month with weekly
      reductions up to 5 mg/day at the end of the second month). Induction therapy consisted of
      basiliximab or antithymocyte globulin (Thymoglobulin, Genzyme®). Thymoglobulin will be used
      in patients with panel reactivity class I greater than 50 % (at a dose of 1mg/kg for 5 days).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2014</start_date>
  <completion_date type="Actual">January 2016</completion_date>
  <primary_completion_date type="Actual">January 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in estimated glomerular filtration rate from baseline</measure>
    <time_frame>Baseline, 1 month, 3 months, 6 months and 12 months</time_frame>
    <description>The primary end-point will be evaluated the estimated glomerular filtration rate (eGFR) over 12 months of renal transplantation. The investigators will be measure the change in eGFR during 12 month follow-up. Glomerular filtration rate will be estimated by the MDRD equation (Modification of Diet in Renal Disease).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of cytomegalovirus Infection (CMV)</measure>
    <time_frame>Weekly from baseline until the third month. After in 4, 5, 6, 8, 10 and 12 months.</time_frame>
    <description>The secondary end-point will be evaluated the incidence of cytomegalovirus (CMV) infection. CMV infection will be defined based on detection of CMV viral replication (CMV pp65 antigenemia more than zero) in asymptomatic patients. CMV disease will be defined based on the evidence of CMV infection with related symptoms. For the positive cases treatment will be carried out with ganciclovir 5 mg/kg/day twice daily adjusted for renal function for a minimum of 14 days.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Disorder Related to Renal Transplantation</condition>
  <condition>Cytomegalovirus Infections</condition>
  <arm_group>
    <arm_group_label>Tacrolimus + Mycophenolate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The investigators wil be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8ng/ml at the third month and then 3-7ng/ml from the third month to the 12th month) and mycophenolate sodium 720 mg twice daily. A dose reduction of mycophenolate sodium to 720 mg/day will be accepted due to possible side effects of the drug.
Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tacrolimus + Sirolimus</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The investigators will be used tacrolimus (starting with 0.1 mg/kg twice daily adjusted to target serum levels by 4-8 ng/ml at the third month and then 3-7 ng/ml from the third month to the 12th month) and sirolimus 2 mg/day (adjusted serum levels at 4-8 ng/ml throughout the study period).
Prednisone 30 mg/day in the first month. Induction therapy consisted of basiliximab or thymoglobulin if panel reactivity class I greater than 50 %</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sirolimus</intervention_name>
    <arm_group_label>Tacrolimus + Sirolimus</arm_group_label>
    <other_name>Rapamycin</other_name>
    <other_name>Rapamune</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <arm_group_label>Tacrolimus + Mycophenolate</arm_group_label>
    <arm_group_label>Tacrolimus + Sirolimus</arm_group_label>
    <other_name>Prograf</other_name>
    <other_name>FK506</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>mycophenolate</intervention_name>
    <arm_group_label>Tacrolimus + Mycophenolate</arm_group_label>
    <other_name>Myfortic</other_name>
    <other_name>Mycophenolate Sodium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <description>Prednisone 30mg/day</description>
    <arm_group_label>Tacrolimus + Mycophenolate</arm_group_label>
    <arm_group_label>Tacrolimus + Sirolimus</arm_group_label>
    <other_name>Meticorten</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Basiliximab</intervention_name>
    <description>Basiliximab 20mg (first and fourth day) if panel reactivity class I less than 50 %</description>
    <arm_group_label>Tacrolimus + Mycophenolate</arm_group_label>
    <arm_group_label>Tacrolimus + Sirolimus</arm_group_label>
    <other_name>Simulect</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thymoglobulin</intervention_name>
    <description>Thymoglobulin at a dose of 1mg/kg for 5 days if panel reactivity class I greater than 50 %</description>
    <arm_group_label>Tacrolimus + Mycophenolate</arm_group_label>
    <arm_group_label>Tacrolimus + Sirolimus</arm_group_label>
    <other_name>antithymocyte globulin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        1. Patients aged more than 60 years and recipients of compatible renal transplant

        Exclusion Criteria:

          1. Receptors of multiple organs;

          2. non-heart beating donors;

          3. donors aged under 5 or over 65 years;

          4. Patients with body mass index greater than 35
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>February 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 5, 2016</study_first_submitted>
  <study_first_submitted_qc>February 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 17, 2016</study_first_posted>
  <last_update_submitted>February 11, 2016</last_update_submitted>
  <last_update_submitted_qc>February 11, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Associação Médico Espírita de Botucatu</investigator_affiliation>
    <investigator_full_name>Luis Gustavo Modelli de Andrade</investigator_full_name>
    <investigator_title>Clinical Professor PhD</investigator_title>
  </responsible_party>
  <keyword>Kidney transplantation</keyword>
  <keyword>sirolimus</keyword>
  <keyword>cytomegalovirus</keyword>
  <keyword>aged</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cytomegalovirus Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Sirolimus</mesh_term>
    <mesh_term>Everolimus</mesh_term>
    <mesh_term>Mycophenolic Acid</mesh_term>
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Basiliximab</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

